Drugs-Real World Outcomes

Scope & Guideline

Unveiling the true effects of drugs in everyday life.

Introduction

Delve into the academic richness of Drugs-Real World Outcomes with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2199-1154
PublisherSPRINGERNATURE
Support Open AccessYes
CountrySwitzerland
TypeJournal
Convergefrom 2014 to 2024
AbbreviationDRUGS-REAL WOR OUTC / Drugs-Real World Outcomes
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The journal 'Drugs - Real World Outcomes' focuses on the application of real-world evidence to understand drug utilization, effectiveness, safety, and outcomes in various patient populations. It aims to bridge the gap between clinical trials and everyday clinical practice by providing insights into how medications perform in real-world settings.
  1. Real-World Evidence Generation:
    The journal emphasizes studies that generate real-world evidence (RWE) to evaluate the effectiveness, safety, and economic impact of drugs in diverse populations.
  2. Pharmacovigilance and Safety Monitoring:
    It includes research on adverse drug reactions and safety monitoring, utilizing databases and registries to identify potential risks associated with medications.
  3. Focus on Vulnerable Populations:
    The journal often highlights studies involving vulnerable populations such as older adults, patients with comorbidities, or those in low-income settings, to understand their unique medication needs.
  4. Comparative Effectiveness Research:
    It publishes comparative studies that assess the effectiveness and safety of different treatment options, helping clinicians make informed decisions.
  5. Cost-Effectiveness Analyses:
    The journal includes economic evaluations to assess the cost-effectiveness of various pharmacotherapies, providing insights for healthcare policy and resource allocation.
Recent publications in 'Drugs - Real World Outcomes' reveal emerging themes that reflect current healthcare challenges and the evolving landscape of pharmacotherapy. These trends indicate a growing interest in specific areas of research that are increasingly relevant to clinicians and healthcare stakeholders.
  1. Mental Health Pharmacotherapy:
    There is a notable increase in studies examining the use of psychotropic medications and their real-world outcomes, reflecting the growing recognition of mental health issues in clinical practice.
  2. Real-World Data Utilization and Methodologies:
    Emerging methodologies for utilizing real-world data, such as advanced analytics and machine learning techniques, are gaining traction, indicating a shift towards more sophisticated research designs.
  3. Integration of Patient-Reported Outcomes:
    The incorporation of patient-reported outcomes (PROs) in studies is on the rise, emphasizing the importance of patient perspectives in assessing drug effectiveness and quality of life.
  4. Impact of COVID-19 on Medication Use:
    Research exploring the impact of the COVID-19 pandemic on medication utilization patterns and healthcare access is trending, highlighting the pandemic's long-term effects on pharmacotherapy.
  5. Polypharmacy and Medication Management in Older Adults:
    Studies addressing the challenges of polypharmacy and medication management in older adults are increasingly prevalent, reflecting the need for tailored approaches in this demographic.

Declining or Waning

While 'Drugs - Real World Outcomes' has maintained a broad focus on real-world drug utilization and outcomes, certain themes appear to be declining in frequency and prominence over recent years. These waning scopes suggest a shift in research priorities within the journal.
  1. Traditional Drug Use Studies:
    There seems to be a decline in studies focusing solely on traditional drug use patterns without the integration of real-world outcomes or comparative effectiveness.
  2. Basic Pharmacological Mechanisms:
    Papers focusing primarily on the pharmacological mechanisms of drugs without real-world applicability or patient-centered outcomes are becoming less common.
  3. Single-Center Studies:
    The prevalence of single-center studies is decreasing, with a shift towards larger, multi-center studies that provide broader insights into drug outcomes.
  4. Preclinical and Experimental Studies:
    Research that emphasizes preclinical or laboratory-based findings rather than clinical or real-world applications appears to be less favored in recent publications.
  5. Narrow Therapeutic Areas:
    There is a noticeable decrease in papers focused on very specific therapeutic areas, as the journal seems to be favoring broader studies that encompass multiple conditions.

Similar Journals

Journal of Comparative Effectiveness Research

Connecting research to practice for better health solutions.
Publisher: Becaris PublishingISSN: 2042-6305Frequency: 18 issues/year

Journal of Comparative Effectiveness Research is a leading academic journal dedicated to the evaluation of healthcare interventions and practices, published by Becaris Publishing. Since transitioning to a fully Open Access model in 2023, the journal has expanded its accessibility to a global audience of researchers, healthcare professionals, and policy makers. With a focus on comparative effectiveness in health policy, it has achieved a notable ranking of #132 out of 310 in the Scopus category for Medicine and Health Policy, placing it in the 57th percentile for scholarly impact. Operating from the United Kingdom, the journal encompasses research from 2012 to 2024 and firmly establishes itself in the academic landscape as a Q2 journal in the Health Policy category as of 2023. By disseminating high-quality, evidence-based research, the Journal of Comparative Effectiveness Research plays a vital role in informing clinical practice and health policy decision-making, making it an essential resource for those dedicated to improving health outcomes.

CLINICAL NEUROPHARMACOLOGY

Advancing Neurological Insights Through Pharmacology
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0362-5664Frequency: 6 issues/year

CLINICAL NEUROPHARMACOLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal dedicated to advancing the understanding of pharmacological interventions in the realm of neurology. With its ISSN 0362-5664 and E-ISSN 1537-162X, this journal has been a vital resource since its inception in 1982, consistently contributing valuable research and reviews to the fields of clinical neurology and pharmacology. As reflected in its 2023 Quartile Ranking of Q3 in neuroscience and pharmacological categories, CLINICAL NEUROPHARMACOLOGY plays a crucial role in disseminating knowledge among researchers and clinicians alike, showcasing innovative studies that enhance therapeutic practices. The journal promotes rigorous peer-reviewed scholarship and emphasizes access to cutting-edge findings, making it an essential read for professionals aiming to bridge the gap between research and clinical application. Although it operates on a subscription model, the depth and quality of research it presents ensure its significance and utility in advancing the science of neurological pharmacotherapy. For anyone invested in the synergy of pharmacology and neurology, CLINICAL NEUROPHARMACOLOGY is the premier destination for insightful and impactful scholarly communication.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Pioneering insights in pharmacological safety and efficacy.
Publisher: WILEYISSN: 1053-8569Frequency: 12 issues/year

Pharmacopidemiology and Drug Safety is a prestigious academic journal published by Wiley, dedicated to exploring the field of pharmacology and epidemiological studies since its inception in 1992. With its ISSN 1053-8569 and E-ISSN 1099-1557, the journal has achieved notable recognition, ranking Q2 in Epidemiology and Q1 in Medical Pharmacology in the 2023 category quartiles. Its Scopus rankings further enhance its reputation, placing it at 105th in the field of pharmacology and at 63rd in epidemiology, reflecting its commitment to publishing high-quality research that informs clinical practices and public health policies. Although it operates under a subscription model rather than open access, Pharmacopidemiology and Drug Safety plays a critical role in disseminating vital knowledge regarding drug safety and effectiveness, making it an essential resource for researchers, professionals, and students looking to stay at the forefront of advancements in the medical field.

Therapeutic Advances in Drug Safety

Connecting Researchers and Practitioners for Safer Therapies
Publisher: SAGE PUBLICATIONS LTDISSN: 2042-0986Frequency: 1 issue/year

Therapeutic Advances in Drug Safety is a prestigious open-access journal published by SAGE Publications Ltd that has made significant strides in the field of pharmacology since its inception in 2010. With an impressive impact factor that places it in the Q1 category for Pharmacology (medical), this journal ranks 61st out of 272 in Scopus, showcasing its global influence and commitment to advancing drug safety research. Based in the United Kingdom, it aims to bridge the critical gap between pharmacological innovation and clinical application, offering a platform for the dissemination of groundbreaking research, case studies, and expert reviews. Since adopting an Open Access model in 2019, the journal has significantly increased its reach, ensuring that vital findings in drug safety are accessible to researchers, healthcare professionals, and educators worldwide. As the field of drug safety continues to evolve, Therapeutic Advances in Drug Safety remains an essential resource for those dedicated to enhancing safe therapeutic practices and patient outcomes.

Journal of Managed Care & Specialty Pharmacy

Connecting Research and Practice for Enhanced Patient Care
Publisher: ACAD MANAGED CARE PHARMACYISSN: 2376-0540Frequency: 12 issues/year

The Journal of Managed Care & Specialty Pharmacy is a premier publication in the realm of health policy and pharmaceutical science, dedicated to enhancing the understanding and practices surrounding managed care systems and specialty medications. Published by ACAD MANAGED CARE PHARMACY, this journal boasts an impressive Q1 ranking in both Pharmaceutical Science and Pharmacy, underscoring its significance in advancing professional discourse and research in these critical areas. With a focus on innovative care strategies and patient-centered approaches, it aims to share impactful research, reviews, and opinions that shape the future of health policy and pharmaceutical practices. The journal is available in an open access format, ensuring that vital information is universally accessible to researchers, practitioners, and policymakers alike. With its inception in 2014 and an ongoing commitment to excellence through 2024, the journal is firmly established as a leading resource within its field, making it essential reading for professionals dedicated to improving managed care and specialty pharmacy solutions.

VALUE IN HEALTH

Fostering Global Health Improvement Through Rigorous Scholarship
Publisher: ELSEVIER SCIENCE INCISSN: 1098-3015Frequency: 12 issues/year

VALUE IN HEALTH, published by Elsevier Science Inc, is a premier peer-reviewed journal in the fields of Health Policy, Medicine, and Public Health. With an impressive impact factor reflecting its respected standing, the journal has achieved a distinguished Q1 classification in multiple categories, placing it among the top publications in the health domain. Since its inception in 1998, this journal has been a vital platform for disseminating research that informs health policy and practice, impacting both clinical and public health decision-making. The journal’s Scopus rankings further underscore its global influence, with notable positions in Medicine and Public Health sectors. VALUE IN HEALTH is committed to fostering an environment where innovative research meets practical application, ultimately aiming to enhance health outcomes worldwide. Researchers, professionals, and students alike are encouraged to explore the wealth of knowledge contained within its pages.

Safety

Empowering a safer tomorrow with open access insights.
Publisher: MDPIISSN: Frequency: 4 issues/year

Safety is a prestigious Open Access journal published by MDPI, based in Switzerland, dedicated to advancing research in the fields of public health, environmental safety, and occupational health. Since its inception in 2015, the journal has become a vital resource for researchers, practitioners, and policymakers, striving to foster innovative solutions to safety challenges in various sectors. With its rigorous peer-review process and a 2023 ranking in the Q2 category for Safety Research, as well as a notable presence in public health and environmental disciplines, Safety is well-respected in academic circles, holding a Scopus rank of 37/109 in Safety Research and 87/207 in Safety, Risk, Reliability, and Quality. The journal aims to disseminate high-quality research that not only reflects the latest advancements but also aids in developing practical strategies for risk management and safety improvement. Supported by an open-access model, Safety ensures that cutting-edge research is readily available to a global audience, fostering collaboration and knowledge sharing for a safer environment.

Farmeconomia-Health Economics and Therapeutic Pathways

Connecting research and policy for effective healthcare solutions.
Publisher: SEED MEDICAL PUBLISHERSISSN: 1721-6915Frequency: 1 issue/year

Farmeconomia-Health Economics and Therapeutic Pathways is a pioneering journal within the field of health economics, dedicated to exploring the intersections of health policy, therapeutics, and economic evaluations. Published by SEED MEDICAL PUBLISHERS, this Open Access journal has been at the forefront of advancing knowledge since 2012, ensuring that vital research is readily accessible to a global audience without subscription barriers. The journal aims to facilitate the dissemination of insightful studies, systematic reviews, and theoretical discussions that determine the cost-effectiveness of therapeutic options, ultimately guiding evidence-based healthcare decisions. Based in *Torino, Italy*, this journal is committed to serving researchers, healthcare professionals, and students who are eager to contribute to and stay updated on the latest developments in health economics and policy implementation. With its broad-ranging scope and dedication to quality research, Farmeconomia stands as an essential resource for anyone engaged in the complex dynamics of health systems and their economic implications.

Expert Opinion On Drug Safety

Fostering Scholarly Dialogue on Drug Safety
Publisher: TAYLOR & FRANCIS LTDISSN: 1474-0338Frequency: 6 issues/year

Expert Opinion on Drug Safety is a prestigious academic journal dedicated to advancing knowledge in the fields of drug safety and pharmacology. Published by Taylor & Francis Ltd, this journal serves as an essential resource for researchers and professionals seeking to explore the complexities of drug interactions, adverse effects, and risk management. With an impressive impact factor and recognized as a Q1 journal in both the Medicine (Miscellaneous) and Pharmacology (Medical) categories, it ranks favorably at #78 out of 272 in Scopus, placing it in the 71st percentile among its peers. Operating under a rigorous peer-review process, the journal publishes original research, expert reviews, and opinion pieces that contribute to a deeper understanding of drug safety practices. While not an open access journal, it remains a vital platform for disseminating pivotal findings and fostering scholarly dialogue, ensuring that critical insights reach a global audience. With continuous publication from 2002 to 2024, Expert Opinion on Drug Safety is a key reference for anyone involved in pharmaceutical research, healthcare practice, or drug regulation.

CLINICAL THERAPEUTICS

Innovating pharmacology for a healthier tomorrow.
Publisher: ELSEVIERISSN: 0149-2918Frequency: 12 issues/year

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.